Clairvoyant Therapeutics
29.11.2023 22:46:30 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints.
"We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out in February 2024 and a top line read out in Q2 2024," stated Damian Kettlewell, CEO, Clairvoyant.
"Our goal is to be the first company in the world to obtain regulatory approval for the clinical use of psilocybin in AUD. The medical benefits of psychedelic compounds like psilocybin have been supressed for decades. We are pleased that regulatory authorities are now engaged in evidence-based approaches to review these potentially remarkable compounds."
Clairvoyant has been motivated to explore psilocybin therapy for AUD as a result of pioneering academic work by researchers in the U.S. Positive clinical results will support Clairvoyant's goal to help millions of AUD patients around the world.
Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women (source: WHO Global Status Report on Alcohol and Health 2014). A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications (source: BC Centre for Substance Use, 2023).
About Clairvoyant Therapeutics
Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin therapy. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.
Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov
-30-
For more information:
Damian Kettlewell
damian@clairvoyantrx.com
SOURCE: Clairvoyant Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/810748/clairvoyant-surpasses-50-per-cent-randomization-in-its-phase-2b-psilocybin-therapy-trial-for-alcohol-use-disorder
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Hydrosat and Kazakhstan Gharysh Sapary Sign Agreement to Advance Satellite-Based Water Intelligence Across Kazakhstan and Central Asia25.6.2026 17:00:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / June 25, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, and JSC "NC "Kazakhstan Gharysh Sapary" (JSC "NC "KGS"), Kazakhstan's national space company, announced the signing of a Joint Activity Agreement during a ceremony held in Brussels on 23 June 2026. The agreement establishes the framework for a national-scale program to digitize water resources management using satellite-based thermal analytics and AI, with the potential to expand across Central Asia. The agreement was signed as part of the state visit of the Head of State of the Republic of Kazakhstan to Belgium. During the visit, a number of strategic agreements were concluded to advance artificial intelligence, science, digital infrastructure, and space technologies, creating new opportunities for investment, joint research, technology deployment, and international cooperation. Representing Kazakhstan at the signing ceremonies were Deputy Prime
GA-ASI Adapts Ground Control Station to Fly MQ-9B25.6.2026 16:00:00 CEST | Press release
World Leader in UAS Invests in Upgrades That Ease MQ-9B Procurement SAN DIEGO, CA / ACCESS Newswire / June 25, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is working to adapt its Block 30 Ground Control Stations (GCS) to fly the company's newer model MQ-9B SkyGuardian® and SeaGuardian® Remotely Piloted Aircraft. When these upgrades are complete, they will enable current users of the Block 30 system, originally designed to fly the MQ-9A Reaper®, to keep that equipment and use it to operate the more capable aircraft. Current users include the U.S. Air Force, U.S. Marine Corps, the Italian Air Force, the French Air Force, the United Arab Emirates Armed Forces, the Spanish Air Force, and the Royal Netherlands Air Force. GA-ASI developed the MQ-9B through its own internal research and development. The upgraded new aircraft required a new and more powerful GCS. The ongoing work with the Block 30 GCS now means that prospective users with existing stocks of equipment wouldn't ne
TIS Warns that Companies are Underprepared for Impact of ISO 20022 Financial Transaction Standard25.6.2026 15:30:00 CEST | Press release
Treasury Intelligence Solutions (TIS) reports that payment disruption is now reaching corporates as banks enforce stricter data standards under the new standard for transaction messaging, and critical gaps are appearing. BERLIN, DE / ACCESS Newswire / June 25, 2026 / TIS today announced a call to action for corporate treasury, finance, and IT teams: ISO 20022 is no longer a bank-only issue, and companies that treat it as simply a messaging upgrade may face payment delays, rejected transactions, higher manual intervention, and reconciliation problems. TIS is the creator of an award-winning cloud-based platform for managing global cash flow, liquidity, and payments. Hundreds of worldwide clients rely on the TIS platform for $80 billion in daily cash management and $2.7 trillion in annual transaction volume. The TIS call to action stems from the SWIFT global financial communication network's steps to phase in ISO 20022 as the sole standard for interbank payment instructions. The new stand
Envision Pharma Group Promotes Jennifer Lospinoso to President, Riparian25.6.2026 15:00:00 CEST | Press release
FAIRFIELD, CT / ACCESS Newswire / June 25, 2026 / Envision Pharma Group (Envision) has appointed Jennifer (Jenn) Lospinoso as President of Riparian, its business unit focused on pricing, access, and value optimization for pharmaceutical and biotech companies. "Jenn's promotion reflects her exceptional leadership, deep industry expertise, and unwavering commitment to clients," said Tom Langan, CEO of Envision. "Riparian represents a significant growth opportunity for Envision, and I'm confident that Jenn and her team will drive the innovation and excellence that sets us apart and delivers for our clients." Lospinoso came to Envision as part of the 2022 acquisition of Riparian, where she served as a key leader. Jenn has built a reputation as a trusted advisor to some of the industry's leading pharmaceutical companies, guiding manufacturers through commercial strategy implementation and navigating statutory and regulatory changes across government programs, including the development of pr
Pacific Avenue Capital Partners Announces Investment Committee Appointment, New AI Initiative, and Team Expansion25.6.2026 15:00:00 CEST | Press release
LOS ANGELES, CA / ACCESS Newswire / June 25, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced the appointments of Jonathan Sinnott to the Investment Committee, the establishment of a dedicated artificial intelligence team led by Al Rahrooh and supported by Ahsan Hashmi and Alejandro Urrea, and the addition of Tyler Woodhouse, Adolfo Guerra, and Francisco Lima across portfolio operations and compliance, along with a new investment team member, Saiesha Sharma, as an associate. "We remain committed to building the best private equity firm to work at in Los Angeles. Jonathan's appointment to the Investment Committee is a well-deserved recognition of his contributions and I look forward to his continued impact in this expanded role. Additionally, the establishment of our dedicated AI team is a critical initiative for the firm, and one we believe will cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom